Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P‐Glycoprotein Inhibitor (Itraconazole)
Authors:
- 27 May 2020
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 60 (10) , 1314-1323
Abstract
The effects of itraconazole on the pharmacokinetics of rovatirelin were investigated in an open‐label, single‐sequence drug‐drug interaction study in 16 healthy subjects. Subjects were administered a single oral dose of rovatirelin (1.6 mg) on day 1 and day 15. From day 8 through 16, subjects received daily oral doses of itraconazole (200 mg/day). Concentrations of rovatirelin and (thiazolylalanyl)methylpyrrolidine (TAMP), the major metabolite of rovatirelin formed by cytochrome P450 (CYP) 3A4/5, were determined in plasma and urine. Pharmacokinetic parameters were used to evaluate the drug‐drug interaction potential of rovatirelin as a victim. With coadministration, maximum concentration (Cmax) and area under the concentration‐time curve extrapolated to infinity (AUCinf) of rovatirelin increased 3.05‐fold and 2.82‐fold, respectively, and the 90% confidence intervals of the ratios for Cmax (2.64‐3.52) and AUCinf (2.47‐3.23) did not fall within the 0.8‐1.25 boundaries. Urinary excretion of rovatirelin increased at almost the same ratio as the AUCinf ratio with coadministration; however, renal clearance did not change. Cmax, AUCinf, and urinary excretion of TAMP were decreased by coadministration. Itraconazole has the potential to inhibit drug transport via intestinal P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP); therefore, substrate assessments of rovatirelin for the 2 transporters were evaluated using Caco‐2 cell monolayers. In vitro studies showed that rovatirelin is a substrate for P‐gp but not for BCRP. The current study shows that itraconazole's effect on rovatirelin pharmacokinetics is mediated through inhibition of CYP3A4/5 and intestinal P‐gp.Keywords
This publication has 33 references indexed in Scilit:
- P-gp Inhibition Potential in Cell-Based Models: Which “Calculation” Method is the Most Accurate?The AAPS Journal, 2008
- Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 In VivoClinical Pharmacology & Therapeutics, 2007
- Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P‐glycoproteinBritish Journal of Clinical Pharmacology, 2006
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- Taltirelin Hydrate (TA‐0910): An Orally Active Thyrotropin‐Releasing Hormone Mimetic Agent with Multiple ActionsCNS Drug Reviews, 1998
- Assignment of human thyrotropin-releasing hormone (TRH) receptor gene to chromosome 8Somatic Cell and Molecular Genetics, 1993
- Extrahypothalamic Thyrotropin Releasing Hormone (TRH) — Its distribution and its functionsLife Sciences, 1979
- Peptides in the Brain: The New Endocrinology of the NeuronScience, 1978
- Aspects of Hypothalamic Regulation of the Pituitary GlandScience, 1978